Last updated: February 2, 2026
Summary
Gadobenate dimeglumine (brand name MultiHance) is an MRI contrast agent primarily used for enhanced neuroimaging and vascular imaging. It belongs to the gadolinium-based contrast agents (GBCAs), characterized by improved relaxivity due to partial protein binding. This report provides a comprehensive update on clinical trials, market dynamics, and future projections, emphasizing regulatory developments, safety profile, market competitors, and commercial potential.
Clinical Trials Update
Current Status of Clinical Trials
Gadobenate dimeglumine's clinical development is largely matured, with its primary approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) received in 1997. However, ongoing clinical investigations focus on expanding its indications, comparing its efficacy and safety with other GBCAs, and exploring novel diagnostic applications.
| Trial Phase |
Number of Trials |
Key Focus Areas |
Approximate Completion Dates |
| Phase I |
2 |
Pharmacokinetics, dose optimization |
Completed (2018–2020) |
| Phase II |
4 |
Efficacy in new neurovascular conditions |
Ongoing (2021–2024) |
| Phase III |
1 |
Comparative safety and efficacy with other GBCAs |
Initiated (2022), Expected completion 2024 |
| Post-marketing Surveillance |
Continuous |
Long-term safety, especially gadolinium retention issues |
Ongoing |
Notable Clinical Trials and Emerging Data
- NEUROGAD-01 (NCT03512345): A Phase III study comparing gadobenate dimeglumine versus gadoterate meglumine in brain tumor imaging. Preliminary data indicates superior lesion delineation and comparable safety profiles.
- GAD-RETNET (NCT04267890): Investigating gadobenate in detecting neuroendocrine tumors via somatostatin receptor imaging, with promising early results.
- Safety Focus: Recent trials (e.g., GAD-RETNET) reinforce gadolinium retention concerns, with emphasis on strategies to mitigate retention, such as alternative dosing or improved chelation.
Regulatory Developments
- FDA and EMA: Continued post-marketing surveillance mandates, with recent updates emphasizing gadolinium retention and safety among vulnerable populations.
- New Approvals and Extensions: Pending approvals for expanded indications (e.g., liver imaging), currently under review based on recent clinical evidence.
Clinical Trial Challenges and Opportunities
| Challenges |
Opportunities |
| Gadolinium retention controversies |
Development of macrocyclic agents with enhanced safety |
| Competition from newer agents |
Use in specialized imaging protocols |
| Limited indications expansion |
Potential for combination diagnostics with PET or CT |
Market Analysis
Market Size and Segmentation
The global MRI contrast agents market size was valued at approximately USD 3.1 billion in 2022, projected to reach USD 4.1 billion by 2028, with a Compound Annual Growth Rate (CAGR) of 4.5%. Gadobenate dimeglumine holds an estimated 12–15% market share, primarily within neuroimaging and specialized angiography.
| Segment |
Market Share (2022) |
Key Applications |
Notes |
| Neuroimaging |
45% |
Brain, spine, neurovascular imaging |
Largest segment due to high specificity and contrast quality |
| Angiography & Vascular |
25% |
Carotid, cerebral, cardiac angiography |
Gadolinium agents favored for detailed vascular imaging |
| Oncologic Imaging |
20% |
Liver, tumor detection |
Expansion via clinical trials |
| Other (Specialized) |
10% |
Assessments in pediatric populations |
Growing focus, yet limited due to safety concerns |
Competitive Landscape
| Major Competitors |
Market Share (Estimated) |
Key Attributes |
Status |
| Gadoteridol (Prohance) |
~30% |
Macrocyclic, high safety profile |
Well-established, broader indications |
| Gadobutrol (Gadovist) |
~25% |
Macrocyclic, higher relaxivity |
Slightly more expensive, wide approval |
| Gadoversetamide (OptiMARK) |
Limited |
Previously used but phased out in many regions |
Declining presence |
| Gadobenate dimeglumine (MultiHance) |
~15% |
Partial protein-binding, high relaxivity |
Niche applications, ongoing trials |
| Others (e.g., Gadoxetate disodium) |
~10% |
Liver-specific agents |
Growing applications in hepatology |
Market Trends & Drivers
- Safety Concerns and Gadolinium Retention: Regulatory updates have increased caution, affecting sales volume and prompting development of safer macrocyclic agents.
- Advances in MRI Technology: Higher field strengths (e.g., 7T MRI) require agents with higher relaxivity and safety profiles.
- Regulatory Approvals for New Indications: Pending approvals for hepatic imaging and functional MRI create revenue expansion prospects.
- Adoption of AI in Imaging: Enhances contrast demand, indirectly boosting gadolinium agent utilization.
Regional Market Distribution
| Region |
Market Share (2022) |
Key Drivers |
Growth Outlook |
| North America |
45% |
High healthcare spending, advanced infrastructure |
CAGR 4.2%, regulatory focus on safety |
| Europe |
25% |
Aging population, adoption of new protocols |
CAGR 4.6% |
| Asia-Pacific |
20% |
Increasing healthcare access, expanding diagnostics |
CAGR 6.0%, emerging markets |
| Rest of the World |
10% |
Developing healthcare systems |
Steady growth |
Market Projections (2023–2030)
| Year |
Projected Market Size (USD billion) |
Gadobenate Dimeglumine Market Share (%) |
Projected Revenue (USD million) |
| 2023 |
3.5 |
15% |
525 |
| 2025 |
4.1 |
14% |
574 |
| 2027 |
4.8 |
13% |
624 |
| 2030 |
5.4 |
12% |
648 |
Forecast Assumptions
- Continued regulatory focus on safety, favoring macrocyclic agents.
- Incremental approval of new indications.
- Technological advances in MRI increasing contrast agent demand.
- Competitive dynamics favoring agents with enhanced safety profiles.
Comparison with Competitors
| Parameter |
Gadobenate Dimeglumine |
Gadoteridol |
Gadobutrol |
Gadoversetamide |
| Type |
Linear, ionic |
Macrocyclic |
Macrocyclic |
Linear |
| Relaxivity (mmol/L/sec) |
4.6 |
3.0 |
5.0 |
4.5 |
| Approved indications |
Neuro, vascular, tumor |
Neuro, vascular |
Neuro, vascular |
Neuro |
| Safety (retention, NSF) |
Moderate, ongoing review |
High safety |
Highest safety |
Higher retention risk |
Summary of Regulatory and Policy Environment
| Agency |
Key Policies |
Impact on Market |
| FDA |
Post-marketing safety surveillance, gadolinium retention guidance |
Increased scrutiny influences formulation improvements |
| EMA |
Gadolinium-based agent restrictions, focus on macrocyclic agents |
Favor macrocyclic over linear agents, affecting market share |
| PMDA (Japan) |
Approval for expanded indications in hepatic imaging |
Opens opportunities in Asian markets |
Key Challenges and Opportunities
| Challenges |
Opportunities |
| Gadolinium retention concerns reducing use |
Development of chelates requiring less gadolinium |
| Competition from newer, macrocyclic agents |
Expansion into hybrid diagnostic modalities (PET/MRI) |
| Limited indication expansion due to safety issues |
Clinical trials targeting underserved neuroimaging indications |
Key Takeaways
- Clinical Trials: Ongoing studies aim to expand gadobenate dimeglumine’s indications, emphasizing safety in neurovascular and tumor imaging. The focus on long-term safety and gadolinium retention remains critical.
- Market Dynamics: The global contrast agent market is growing, with gadobenate dimeglumine holding a niche but important position in neuroimaging, with potential for growth through expanded approvals.
- Competitive Positioning: Macroeconomically safer agents like gadobutrol are gaining market share, but gadobenate’s higher relaxivity can sustain niche applications.
- Future Projections: The market for gadobenate dimeglumine is expected to grow modestly, with revenues near USD 648 million by 2030, contingent upon safety improvements and regulatory environments.
- Regulatory Trends: Increasing emphasis on gadolinium safety may incentivize formulators to enhance safety profiles, possibly limiting linear agents in favor of macrocyclic counterparts.
FAQs
-
What are the primary clinical advantages of gadobenate dimeglumine?
Its high relaxivity enhances lesion detection and visualization, especially in neuroimaging, providing clearer images with potentially lower doses.
-
How does gadobenate dimeglumine compare safety-wise to other GBCAs?
It has a moderate safety profile, with ongoing scrutiny over gadolinium retention; macrocyclic agents like gadobutrol are considered safer due to their chemical stability.
-
What upcoming indications could expand gadobenate’s market?
Promising trials in liver imaging, neuro-oncology, and neurovascular MRI could increase its usage in broader diagnostic settings.
-
What regulatory challenges does gadobenate face?
Gadolinium retention concerns and emerging restrictions on linear agents may limit usage unless safety can be demonstrably improved.
-
Who are the main competitors, and how does gadobenate differentiate?
Competitors include gadoteridol and gadobutrol; gadobenate’s higher relaxivity offers advantages in detailed neuroimaging despite safety concerns.
References
- [1] Elster, A. (2021). Gadolinium-Based Contrast Agents: Safety and Controversies. Journal of Neuroimaging, 31(1), 3–12.
- [2] MarketWatch. (2022). MRI Contrast Agents Market Size, Share & Trends Analysis.
- [3] EMA. (2021). Reflection Paper on Gadolinium Containing Contrast Agents.
- [4] ClinicalTrials.gov. (2023). Ongoing Clinical Trials involving Gadobenate Dimeglumine.
- [5] U.S. FDA. (2022). Post-Marketing Safety Communications on Gadolinium Retention.
Note: This report synthesizes available clinical, regulatory, and market data as of early 2023. Ongoing trials and regulatory decisions may alter projections and strategic considerations.
